Small cell lung cancer (SCLC) is the most aggressive subtype of lung cancer that has a dismal prognosis. Patients with SCLC are uniformly treated with chemotherapy plus radiotherapy and recently with immunotherapy; however, emerging molecular evidence suggests this disease represents heterogeneous groups. At the genomic level, in addition to the near universal loss of p53 and Rb1, the loci for all three Myc family members are frequently amplified in a mutually exclusive manner, suggesting their redundant oncogenic function. However, the expression of these factors is associated with specific neuroendocrine markers and distinct histopathology, and yet the contribution of Myc family members to SCLC molecular subtypes have not been clearly delineated. In this study, we explored a novel role of c-Myc and L-Myc as lineage specific factors contributing to SCLC molecular subtypes and histological classification. Integrated analyses of a Bayesian network generated from primary tumor mRNA expression and chromatin state profiling of SCLC cell lines showed that Myc family members impart distinct transcriptional programs associated with lineage state; wherein L-Myc was enriched for neuronal pathways and c-Myc for Notch signaling and epithelial-to-mesenchymal transition. We investigated the functional redundancy of c-Myc and L-Myc, and noted the insufficiency of L-Myc to induce lineage switch in contrast to the potential of c-Myc to induce trans-differentiation from ASCL1-SCLC to a NeuroD1-SCLC characterized by distinct histopathology. Collectively, our findings reveal a previously undescribed role for historically defined general oncogenes, c-Myc and L-Myc, in regulating lineage plasticity across molecular subtypes as well as histological classes. Patel, A et al. 4
Introduction
Small cell lung cancer (SCLC) represents about 15% of all lung cancers with a median survival time of approximately 10 months and 5-year overall survival at 6% (Siegel et al., 2019) . SCLC tumors are characterized by neuroendocrine differentiation, rapid growth, early metastatic spread and poor prognosis (Gazdar et al., 2017) . The standard of care has remained cytotoxic chemotherapy for decades, mainly etoposide combined with a platinum agent (Alvarado-Luna et al., 2016), that are only temporarily effective for the vast majority of patients (Pietanza et al., 2015) . Even with recent developments in immune checkpoint inhibitors, activity against SCLCs when combined with chemotherapy has been marginal with a modest improvement in the median survival (10.3 months vs. 12.3 months) for extensive stage SCLCs treated with immunotherapy (Horn et al., 2018) . These data reflect the urgent need for more effective therapeutics for patients with SCLC. The lack of effective therapeutics for SCLC stands in stark contrast to the breadth of targeted therapies for non-small cell lung cancer (NSCLC), particularly lung adenocarcinoma (Rudin et al., 2019) . This progress in drug development for NSCLCs is largely attributable to a more comprehensive understanding of molecular subtypes and to identification of targetable driver oncogenes (Zappa et al., 2016) . Therefore, better characterization of the molecular subtypes of SCLC should aid future drug development and permit patient stratification for targeted therapies, a strategy that has been remarkably effective for specific subsets of advanced lung adenocarcinoma patients.
Characterization of SCLC subtypes was first noted by morphological differences over three decades ago when human SCLC cell lines were implanted as xenografts and distinguished as two primary subtypes: classical SCLC and variant SCLC (Carney et al., 1985; Gazdar et al. 1985) . The classical subtype featured relatively small cells with high nuclear:cytoplasm ratio Patel, A et al. 5 while the variant subtype exhibited relatively larger cells and moderate amounts of cytoplasm.
However, the World Health Organization (WHO) classification, updated in 2015, histologically recognizes SCLC as a homogenous disease with neuroendocrine features defined by small cells, scant cytoplasm, nuclear morphology with fine granular chromatin and lacking prominent nucleoli, reminiscent of the features of the 'classical' SCLC. The originally described 'variant' subtype may represent combined SCLC with LCNEC in the current classification (Travis et al., 2015) .
More recent efforts to distinguish SCLC molecular subtypes include profiling gene expression and genome-wide methylation in primary human tumors and patient derived xenografts (PDX). Profiling revealed three clusters, with a dichotomy between achaete-scute homologue 1 (ASCL1) and neurogenic differentiation factor 1 (NeuroD1) expression, in addition to a cluster with low expression of both (Poirier et al., 2015) . The expression of ASCL1 and NeuroD1 has been implicated to confer SCLC heterogeneity by imparting distinct transcriptional profiles (Borromeo et al., 2016) . The third neuroendocrine-low cluster led to further classification into two subtypes characterized by transcriptional driver YAP1 or POU class 2 homeobox 3 (POU2F3) (McColl et. Al., 2017, Huang et al., 2018) . SCLC cell line xenograft histology has been correlated with these contrasting factors, where variant SCLC was positively correlated with a higher NeuroD1:ASCL1 ratio and classical SCLC was positively correlated with a higher ASCL1:NeuroD1 ratio in SCLC cell lines (Poirier et al., 2013) .
Recapitulating Myc family members in SCLC genetically engineered mouse models (GEMMs) has provided insight in their contribution to histopathological characteristics (Brägelmann et al., 2017 , Kim et al., 2016 . The classical SCLC GEMM with conditional loss of Patel, A et al. 6 Rb1 and Trp53 mouse, harbored stochastic MYCL amplifications or overexpression associated with classical SCLC histopathology (Meuwiseen et al., 2003) . On the contrary, consistent with the original report on the variant subtype to harbor frequent MYC amplification (Gazdar et al. 1985 ), a more recent study showed that additional c-Myc overexpression, in a classical SCLC GEMM drives the progression of murine SCLC with variant histopathology and reduced neuroendocrine gene expression including ASCL1 but higher NeuroD1 expression (Mollaoglu et al., 2017) . Yet, the molecular mechanisms underlying the distinction between L-Myc and c-Myc driven subsets of SCLC remain unexplored. ). c-Myc is a well-characterized oncogene; L-Myc although understudied is implicated to have a similar oncogenic role. Amplification of Myc family members is mutually exclusive and overall accounts for ~20% of SCLC and overexpression for ~50% of SCLC in primary human tumors (George et al., 2015) . In contrast to the fact that MYC is commonly amplified across all three major lung cancer subtypes: lung adenocarcinomas, squamous cell lung carcinomas and SCLC (Weir et al., 2007 , Hammerman et al., 2012 , George et al., 2015 , MYCL and MYCN are uniquely amplified in SCLC, in a manner suggestive of their role as lineage-amplified genes.
In this study, we explore a novel role of c-Myc and L-Myc as lineage specific factors to associate SCLC molecular subtypes with histological classes. We investigated the potential of L-Myc and c-Myc to regulate lineage state and identified transcriptional programs unique to each Myc family member, wherein L-Myc regulates neuronal developmental pathways and c-Myc regulates epithelial-to-mesenchymal transition and Notch signaling, biological pathways that are associated with distinct molecular subsets. In addition, we showed the requirement of c-Myc to maintain lineage state marker NeuroD1, in NeuroD1-positive SCLC and the incompatibility of c-Myc with ASCL1-positive SCLC that ultimately leads to trans-differentiation to NeuroD1-driven SCLC characterized by variant histopathology mediated by a transcriptional repressor, Rest.
Results

SCLC network reveals unique and distinct sub-networks for c-Myc and L-Myc
To investigate the biological processes unique to c-Myc and L-Myc in primary SCLC, we built a molecular regulatory network for SCLC. Combining two independent primary SCLC transcriptomic datasets (George et al., 2015 , Jiang et al., 2016 , a Bayesian network was built using the software package RIMBANET (see Methods). The Bayesian network comprised of 8,451 unique genes (nodes) and 9,301 regulations (edges) among these genes. Network neighbors for genes of interest can provide insights into biological functions that genes of interest are associated with (Zhu et al., 2007 , Zhu et al., 2008 , Zhu et al., 2012 . This enables us to discern transcriptional sub-networks associated with c-Myc and L-Myc that may reflect their unique biological role. To this end, we first aimed to generate a signature associated with each factor and then projected the signature to the SCLC Bayesian network to identify specific subnetworks ( Figure 1A ). To generate this signature, we examined MYC and MYCL mRNA expression in SCLC cell lines from Cancer Cell Line Encyclopedia (CCLE) and selected cell lines with either high expression of MYC or MYCL, then defined gene signatures for MYC expressing and MYCL expressing subsets ( Figure S1A ). We identified 457 differentially expressed genes; 147 genes overexpressed in MYC and 310 overexpressed in MYCL in SCLC cell lines (t-test p-value < 0.01 and fold change > 1.5) ( Figure S1B ).
To explore the sub-networks associated with L-Myc, we projected the genes upregulated in MYCL expressing subset onto the network (Methods). We identified one large closed subnetwork (L1, Figure 1B ) comprising of 959 gene nodes that included 120 of 310 genes from the L-Myc signature. Gene ontology analysis of this L-Myc subnetwork revealed enrichments of two biological processes: cell cycle progression and neuronal development ( Figure 1C ). These two pathways have been previously implicated as core descriptors of classical SCLC (Gazdar et al., 2017) . On the other hand, when we projected the c-Myc signature onto the network, the c-Myc network was organized into three unique sub-networks c1, c2 and c3, comprised of 95, 29 and 25 gene nodes, respectively ( Figure 1D ). Each individual c-Myc sub-networks were enriched in three distinct biological processes. Sub-network c1 was enriched for canonical c-Myc functions in transcriptional, translational and metabolic regulation ( Figure 1E ) (Conacci-Sorell et al., 2014). c-Myc sub-network c2 was enriched for Notch signaling pathway ( Figure 1E ), which has been implicated to mediate a transition from neuroendocrine to non-neuroendocrine fate of tumor cells in a murine SCLC model (Lim et al., 2017) . Finally, sub-network c3 was enriched for pathways in epithelial-to-mesenchymal transition ( Figure 1E ); that has been shown to be relevant in the neuroendocrine-low subtype (Zhang et al., 2018) . These functional pathways enriched in subnetworks c2 and c3 imply previously uncharacterized role of c-Myc in lineage state determination in SCLC.
Together, these findings suggest that c-Myc and L-Myc are associated with differential molecular mechanisms that have been implicated in SCLC biology. Specifically, it implicates c-Myc is associated with neuroendocrine-low differentiation state in addition to its canonical Patel, A et al. 9 oncogenic functions in SCLC, and by contrast, L-Myc is associated with classic neuroendocrine state of SCLC.
c-Myc and L-Myc driven SCLCs exhibit distinct chromatin states
Next, we sought to determine whether the distinct c-Myc and L-Myc networks are associated with their distinct cistromes. To select an appropriate model system to examine the role of each Myc family member, we examined copy number alteration and expression for each Myc family member in 49 SCLC cell lines from CCLE and classified them into four groups representing each Myc family member and low Myc ( Figure S1C ). Based on this classification, we selected representative cell lines for c-Myc (NCI-H82, NCI-H524, NCI-H2171 and NCI-H2081) and L-Myc (CORL-88, NCI-H1963 and NCI-H209) and confirmed protein expression for these transcription factors (Figure 2A Figure S3C ). We observed a fraction of peaks (cluster 1; Figure 2D ) that overlap between c-Myc classified and L-Myc classified cells, suggestive of common functional binding that the Myc family members share. We also found distinct groups of peaks with higher signal intensity unique to L-Myc classified cells (cluster 2; Figure 2D ) and in c-Myc classified cell lines (cluster 3; Figure 2D ). Of note, the chromatin landscape of NCI-H82 appeared to be intermediate to the L-Myc and c-Myc profiles. Together, these findings suggest that c-Myc and L-Myc impart differential transcriptional programs.
Myc family members exert differential transcriptional programs
To gain insights into the unique biological processes c-Myc and L-Myc may impart, we Figure S3D ). On the other hand, L-Myc expression was enriched in the neuroendocrine high ASCL1 subtype ( Figure S3E ). We further sought to reproduce the classification with data from primary tumors (George et al., 2015) and CCLE cell lines with additional data from 79 primary tumors (Jiang et al., 2016) ( Figure S3F ). Of note, while our unsupervised clustering was in general agreement with the published classification (Rudin et al., 2019) , distinction between ASCL1 and NeuroD1 subtypes was relatively ambiguous. In particular, a small distinctive cluster within the NeuroD1 cluster in our dendrogram segregates other samples previously classified as NeuroD1 subtype which clustered closer to the ASCL1 cluster. In this classification, we found that the expression of c-Myc was higher in neuroendocrine low: POU2F3 and YAP1 while L-Myc was higher in ASCL1 and NeuroD1 subtype. Within neuroendocrine subtypes, the difference of c-Myc expression between ASCL1 and NeuroD1 subtypes was not statistically significant. We noted, however, c-Myc expression was significantly higher in samples categorized in NeuroD1 with a higher NeuroD1:ASCL1 ratio (as originally described in Poirier et al., 2015) ( Figure S3I ). The discrepancy may imply an important distinction between the biology of cell lines and primary tumors and/or the heterogeneity of primary tumors with the dual expression of ASCL1 and NeuroD1 in a significant proportion of NeuroD1 classified tumors ( Figure S3F ), which may indeed reflect lineage transition. Together, these data suggest the dichotomy of c-Myc and L-Myc expression in ASCL1-SCLC.
c-Myc plays a dominant role in lineage specification
Given that L-Myc and c-Myc expression are enriched in distinct subtype(s) and they regulate programs associated with its respective subtype, we hypothesized that part of the role Myc family members play is to serve as a lineage factor. To test the potential of L-Myc to establish the neuroendocrine lineage, we modified a c-Myc expressing NeuroD1 classified cell line NCI-H82 by exogenous overexpression of L-Myc and CRISPR-Cas9 mediated deletion of c-Myc. We found c-Myc expressing cell line (NCI-H82) was able to tolerate the over-expression of L-Myc ( Figure 4A ). Cells engineered to express both L-Myc and c-Myc exhibited a modest increase in proliferation rates compared to parental cells expressing only c-Myc ( Figure 4B ). We further demonstrated that replacement of c-Myc with the expression of L-Myc allowed the cells to retain proliferative potential in the absence of c-Myc in NCI-H82 ( Figure 4B ). This indicates redundant roles among the two Myc family members in regards to maintaining cell viability.
To inquire their contribution to lineage determination, we profiled the expression of 
Aurora Kinase A Inhibition sensitivity is altered with change in Myc status
Previous findings suggest that MYC (c-Myc)-driven SCLC is more responsive to Aurora Figure S5B ). On the other hand, overexpression of c-Myc increased sensitivity at lower concentrations of the drug ( Figure S5C ). This suggests either alisertib sensitivity is attributable to c-Myc driven lineage state of the cells, or difference in molecular interaction of Aurora kinase A with each Myc protein.
c-Myc causes loss of classical neuroendocrine SCLC features
The dependency of lineage state marker NeuroD1 on c-Myc led us to hypothesize that c-Myc exerts a role in addition to its oncogenic role to regulate and establish a variant differentiation state. To this end, we genetically engineered a neuroendocrine L-Myc expressing cell lines NCI-H1963 with inducible exogenous overexpression of c-Myc ( Figure 5A ). Of note, exogenous expression of c-Myc led to downregulation of L-Myc in NCI-H1963.
When c-Myc expression is introduced in neuroendocrine-high MYCL-amplified NCI-H1963, we observed an initial phase of growth suppression ( Figure 5B ). This observation stands in contrast to the established role of c-Myc to promote cell cycle and cell proliferation (Dang, 2012). The growth suppression is unlikely to be due to oncogene induced senescence as these cells are deficient for Rb1 and p53 and did not stain positive for beta galactosidase ( Figure S6A ).
Next, we investigated the cell cycle dynamics of NCI-H1963 c-Myc expressing cells in their growth suppressive phase, and found that initial c-Myc expression (day 2) modestly increased the proportion of cells in S and G2/M phase but did not significantly alter the distribution of cells or induce cell cycle arrest to explain slower cell growth ( Figure S6B ). Alternatively, we sought to investigate whether NCI-H1963 cells that did not tolerate the expression of c-Myc reached cell death. We investigated the proportion of Annexin-V positive cells on day 2 and found c-Myc overexpression increased the proportion of necrotic and apoptotic cells as compared to control cells ( Figure 5C ).
We hypothesized that the cell death was a consequence of incompatibility of the neuroendocrine differentiation state with c-Myc expression and that the persisting cells eventually grown out were cells that tolerated the expression of c-Myc, potentially by switching into a differentiation state compatible with c-Myc expression ( Figure 5B ). Therefore, to inquire if the tolerant cells transitioned to an altered lineage state, we investigated the expression of lineage state markers and found that the overexpression of c-Myc downregulated ASCL1 and upregulated NeuroD1 in H1963 cells ( Figure 5A Although we did not observe an enrichment for an active Notch signaling signature amongst the upregulated genes, when we investigated the expression of known Notch signaling pathway targets in trans-differentiated NCI-H1963, we identified Notch-target RE-1 Silencing transcription factor (REST) that is a transcriptional repressor of neuronal genes and ASCL1 (Lim et al, 2017) as one of the genes that were induced upon c-Myc expression ( Figure S7B ) and we confirmed this with protein expression ( Figure S7C ). Therefore, we sought to investigate the c-Myc-Notch-Rest axis in mediating trans-differentiation, we pharmacologically inhibited 
Discussion
In this study, we showed a novel functional distinction between c-Myc and L-Myc in SCLC, in contrast to the prevailing notion that molecular function of Myc family members are similar to each other (Kim et al., 2016) . We found c-Myc is associated not only with canonical roles including transcriptional and translational regulation, but also with lineage associated pathways such as Notch signaling and epithelial-mesenchymal transitions. Our findings are supported by a previous report that described active Notch signaling negatively regulating neuroendocrine lineage by suppressing the expression of ASCL1 (Lim et al., 2017) as well as a study that showed mesenchymal-like features in neuroendocrine-low sub-type of SCLC (Zhang et al., 2018) . By contrast, we found L-Myc is associated with neuronal pathways implicating their relevancy in determining the classical neuroendocrine state of SCLC. These findings are consistent with previous work showing a correlation of expression between L-Myc and neuronal proteins (Kim et al., 2006) . Taken together, contrary to the notion that Myc family members, c-Myc in particular, exclusively act as oncogenes and general amplifiers of expression, our data suggest that they additionally exert lineage defining transcriptional programs (Lin et al., 2012) . We propose that the Myc family members regulate a defined set of transcriptional programs that are essential in SCLC lineage subtype determination. Of note, although these biological pathways associated with these factors have been shown to be relevant for lineage maintenance and determination in distinct subtypes of SCLC but their association with Myc family members has not been described before.
We found L-Myc failed to induce the expression of neuroendocrine lineage state marker, SCLC is a recalcitrant disease typically characterized by neuroendocrine differentiation, nonetheless approximately 10-20% of SCLCs may lack expression of diagnostic neuroendocrine markers (Rekhtman, 2010). Here we report, the plasticity between these histological subtypes and molecular subtypes regulated by c-Myc and L-Myc. The role in lineage determination and maintenance for this family of transcription factors is striking since the Myc family has historically been grouped as general oncogenes. Our data suggests that the role of Myc family in SCLC tumorigenesis could be re-defined. This will enable us to categorize these subtypes to develop effective therapies to combat this highly lethal disease.
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Methods
CCLE RNA-seq analysis
RNA-seq gene expression data and SNP-array copy number data for MYC, MYCL and MYCN were downloaded from (CCLE) web site (http://www.broadinstitute.org/ccle/home).
Log2(TPM (transcripts per million) +1) values for mRNA expression and log2(inferred copy number/2) values for copy numbers were used to depict a heatmap for a 49 SCLC cell lines. was performed at Tisch Cancer Institute sequencing core on the NextSeq500 (Illumina) for 38 nucleotides each from paired ends according to manufacturer's instructions.
Bayesian Network Analysis
ATAC-seq data analysis
Illumina sequencing adapter was removed using Cutadapt from raw sequence files in fastq format. The reads were aligned to the hg19 reference genome using Bowtie2 with -k 1 parameters. The aligned reads were used to eliminate PCR duplicates using samtools and filtered off an ATAC blacklist for mitochondrial DNA homologs generated by Buenostro et al.,
2015.
Fragment ends were shifted +4 nucleotides for positive strand and -5 for negative strand to account for distance from Tn5 binding and helicase activity to identify cut sites. Extended Tn5 cut sites were used for peak calling with MACS2 with parameters --nomodel --extsize 100 --shift Supplementary   Table S3 . sgRNAs were cloned using BbsI site downstream of the human U6 promoter in a lentiviral vector containing EGFP downstream of the human PGK promoter (a kind gift of Brown laboratory, ISMMS). Lentivirus was produced as described above. Cas9 expressing cells were then infected with pLenti-GFP-sgRNA.
Cell proliferation assay
Cells were plated at a density of 5,000 cells/well with five replicates in a 96-well plate; four identical plates were prepared. Cell viability was assayed at 0, 2, 4 and 6 days after plating with alamarBlue Cell Viability Reagent (Thermo Fisher Scientific) and fluorescence at 585 nm was measured on a Spectra Max3 plate reader (Molecular Device) according to the manufacturer's protocol at excitation of 555 nm. Cell viability at 2, 4 and 6 days were corrected for the ratio to control cells from the day 0 reading to account for plating unevenness. 
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